Novo Nordisk shares fell 30% in the fourth quarter on disappointing clinical trial data, concerns about its experimental ...

Under the expanded collaboration, Valo's Opal Computational Platform will be integrated with Novo Nordisk's expertise in cardiometabolic diseases, deriving insights from real-world patient data, ...

Novo Nordisk expanded a deal with Valo Health to discover and develop treatments for obesity, type 2 diabetes and cardiovascular disease using human data and artificial intelligence. The deal extends ...

At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...

Novo Nordisk is doubling down on its collaboration with Valo Health, committing up to $190 million in near-term payments—and ...

Scope of collaboration originally signed in 2023 will significantly expand to enable the discovery and development of up to 20 novel drug ...

Novo Nordisk (NVO) and Valo Health expand collaboration to develop new treatments targeting cardiometabolic diseases. Read ...

Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Neutral ...

It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, including in the U.S.

JUST IN: Trump calls into Trump Jr.’s visit to Greenland, makes the argument for why the country should join American ...

After holding leadership positions at contract manufacturers Patheon and Thermo Fisher Scientific, working in the food and ...